Scientific understanding of approved drugs remains severely limited
Russ Altman · a16z Podcast | The Genetics Of Drug Delivery · Jan 2, 2019 · at 3:52
This episode carries Russ Altman's own address, with nobody on the show putting questions to them. It still counts as said, and it is kept out of every score on their page.
Dr. Russ Altman, Stanford bioengineering professor and co-founder of PharmGKB, discusses the blind spots in modern pharmaceutical drug development.
0:00 / 0:07exact quote · 7.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Even for drugs that are on the market, and have been used for many years, our ability to really describe what they actually do is very limited.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Russ Altman
Combining Paxil and Pravastatin causes unexpected spikes in blood glucose levels
“And in one story that I'll just summarize very briefly, we looked for drugs that might cause glucose in, glucose increases, diabetes, if you will, in combination, where individually, they did nothing. So we had a very strong signal that the drugs, when taken a…”
Microsoft search logs revealed unreported side effects of combining common drugs
“In a collaboration with Microsoft, we looked at what people who were on, well, we don't know if they were on these drugs. We just looked at search logs and said, how often do people type in these two drugs and words that might be associated with the symptoms o…”
Data mining reveals tens to hundreds of unlisted side effects per drug
“We were able to find replicate what was on the drug label, but using the exact same methods, we were able to find tens or hundreds of extra side effects per drug with very high confidence from looking at a combination of FDA records and electronic medical reco…”
Pharma must mine social media and online portals for side effects
“All of these also, it's clear, I think, to most pharmaceuticals have to be sources of data, both for understanding the actions of these drugs, but also understanding the patient preferences about which symptoms of these diseases they're really most interested …”
Insights for repurposing drugs come from side effects, not approved labels
“If you're going to repurpose a drug, though, All the information in the drug label that was focused on getting you approved for one indication is not going to be where you're going to get the insight about the new uses. You're going to get the insight about th…”